We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
151
Moderna
MRNA
$21.5B
$227K ﹤0.01%
7,711
-1,630
-17% -$44.3K
CRNX icon
152
Crinetics Pharmaceuticals
CRNX
$8.86B
$188K ﹤0.01%
+4,040
New +$180K
ALKS icon
153
Alkermes
ALKS
$8.82B
$185K ﹤0.01%
6,594
– –
COR icon
154
Cencora
COR
$60.3B
$176K ﹤0.01%
521
-4,329
-89% -$1.48M
CAI
155
Caris Life Sciences
CAI
$4.39B
$173K ﹤0.01%
6,418
-3,187
-33% -$89.8K
IDYA icon
156
IDEAYA Biosciences
IDYA
$3.41B
$171K ﹤0.01%
+4,942
New +$158K
TVTX icon
157
Travere Therapeutics
TVTX
$5.33B
$146K ﹤0.01%
+3,827
New +$124K
CGON icon
158
CG Oncology
CGON
$6.11B
$129K ﹤0.01%
+3,095
New +$128K
DNLI icon
159
Denali Therapeutics
DNLI
$3.67B
$118K ﹤0.01%
+7,138
New +$120K
QURE icon
160
uniQure
QURE
$2.68B
$114K ﹤0.01%
4,763
– –
APLS
161
DELISTED
Apellis Pharmaceuticals
APLS
$106K ﹤0.01%
+4,210
New +$98.8K
AMRX icon
162
Amneal Pharmaceuticals
AMRX
$5.72B
$99.7K ﹤0.01%
7,913
– –
CRSP icon
163
CRISPR Therapeutics
CRSP
$4.58B
$98.6K ﹤0.01%
+1,880
New +$113K
OLMA icon
164
Olema Pharmaceuticals
OLMA
$1.02B
$97.5K ﹤0.01%
+3,902
New +$69.4K
TRVI icon
165
Trevi Therapeutics
TRVI
$2.49B
$95.2K ﹤0.01%
+7,603
New +$87.9K
GMAB icon
166
Genmab
GMAB
$17.7B
$92.7K ﹤0.01%
3,009
– –
ZTS icon
167
Zoetis
ZTS
$31.6B
$91.7K ﹤0.01%
729
-143
-16% -$18.7K
TYRA icon
168
Tyra Biosciences
TYRA
$1.82B
$82.6K ﹤0.01%
+3,143
New +$57.7K
ORIC icon
169
Oric Pharmaceuticals
ORIC
$1.25B
$79.4K ﹤0.01%
+9,706
New +$112K
RARE icon
170
Ultragenyx Pharmaceutical
RARE
$2.65B
$59.3K ﹤0.01%
+2,580
New +$84.8K
MTD icon
171
Mettler-Toledo International
MTD
$26.8B
$53K ﹤0.01%
38
-4
-10% -$5.59K
A icon
172
Agilent Technologies
A
$39.1B
$47.6K ﹤0.01%
350
-456
-57% -$65.5K
ORCL icon
173
Oracle
ORCL
$331B
$39.6K ﹤0.01%
203
-214
-51% -$51K
QCOM icon
174
Qualcomm
QCOM
$176B
$35.7K ﹤0.01%
209
-238
-53% -$40.8K
NTLA icon
175
Intellia Therapeutics
NTLA
$1.5B
$26.8K ﹤0.01%
+2,978
New +$41K
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.